Zobrazeno 1 - 10
of 258
pro vyhledávání: '"Andre C. Schuh"'
Autor:
May Chiu, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Hassan Sibai, Karen Yee, Marta Davidson, Steven M. Chan, Vikas Gupta, Dawn Maze
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-5 (2024)
Externí odkaz:
https://doaj.org/article/c7a90e66b1a74df39d5b68d84be53494
Autor:
Maria Agustina Perusini, Claire Andrews, Eshetu G. Atenafu, Vikas Gupta, Dawn Maze, Andre C. Schuh, Karen WL. Yee, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Steven M. Chan, Jad Sibai, Aaron D. Schimmer, Mark D. Minden, Hassan Sibai
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTThis retrospective report presents the outcomes and adverse events (AEs) observed in 73 patients aged 60 years or older diagnosed with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia (Ph-negative ALL) treated with a pediatric-in
Externí odkaz:
https://doaj.org/article/860fe86b5d6c425b93b7c8cf45f165fa
Autor:
Julie Bergeron, Jose-Mario Capo-Chichi, Hubert Tsui, Etienne Mahe, Philip Berardi, Mark D. Minden, Joseph M. Brandwein, Andre C. Schuh
Publikováno v:
Current Oncology, Vol 30, Iss 12, Pp 10410-10436 (2023)
FMS-like tyrosine kinase 3 (FLT3) mutations are detected in approximately 20–30% of patients with acute myeloid leukemia (AML), with the presence of a FLT3 internal tandem duplication (FLT3-ITD) mutation being associated with an inferior outcome. A
Externí odkaz:
https://doaj.org/article/1416eca2cc7b4404a0ee2c558a41f7d4
Autor:
Ibrahim Al Nabhani, Claire Andrews, Jad Sibai, Eshetu Atenafu, Taylor Young, Steven M. Chan, Vikas Gupta, Dawn Maze, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai
Publikováno v:
eJHaem, Vol 4, Iss 1, Pp 232-235 (2023)
Abstract PEG‐asparaginase is used as a treatment for Philadelphia‐negative acute lymphoblastic leukemia. In pediatric studies, triglycerides (TGs) were affected more by PEG‐asparaginase than by native L‐asparaginase (10.0% vs. 5.5%). We condu
Externí odkaz:
https://doaj.org/article/e50e7e9e08b74513abd28ce4a7d9068c
Autor:
Kimberly Guinan, Karine Mathurin, Yunghan Au, Andre C. Schuh, Cat N. Bui, Xinglei Chai, Jean Lachaine
Publikováno v:
Current Oncology, Vol 29, Iss 10, Pp 7524-7536 (2022)
Treatment for acute myeloid leukemia (AML) typically involves intensive chemotherapy (IC); however, there is an unmet need for approximately 50% of AML patients who are deemed unfit or ineligible for IC. The purpose of this study was to evaluate, fro
Externí odkaz:
https://doaj.org/article/bf0b243931014d68b508d082835e8efb
Autor:
Anne Tierens, Elizabeth Kagotho, Satoru Shinriki, Andrew Seto, Adam C. Smith, Melanie Care, Dawn Maze, Hassan Sibai, Karen W. Yee, Andre C. Schuh, Dennis Dong Hwan Kim, Vikas Gupta, Mark D. Minden, Hirotaka Matsui, José-Mario Capo-Chichi
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionInherited DDX41 mutations cause familial predisposition to hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), with the majority of DDX41 mutated MDS/AMLs described to date harboring germli
Externí odkaz:
https://doaj.org/article/ed7c8962d5984554ac1f4f6ebf6e56b8
Autor:
Andrew H. Wei, Gail J. Roboz, Herve Dombret, Hartmut Dohner, Andre C. Schuh, Pau Montesinos, Dominik Selleslag, Sergey N. Bondarenko, Thomas Prebet, Yinzhi Lai, Barry Skikne, C.L. Beach, Farhad Ravandi
Publikováno v:
Haematologica, Vol 108, Iss 10 (2023)
Externí odkaz:
https://doaj.org/article/44db1ff7fbd34a46942b49b93e5add13
Autor:
Keith W. Pratz, Panayiotis Panayiotidis, Christian Recher, Xudong Wei, Brian A. Jonas, Pau Montesinos, Vladimir Ivanov, Andre C. Schuh, Courtney D. DiNardo, Jan Novak, Vlatko Pejsa, Don Stevens, Su-Peng Yeh, Inho Kim, Mehmet Turgut, Nicola Fracchiolla, Kazuhito Yamamoto, Yishai Ofran, Andrew H. Wei, Cat N. Bui, Katy Benjamin, Rajesh Kamalakar, Jalaja Potluri, Wellington Mendes, Jacob Devine, Walter Fiedler
Publikováno v:
Blood Cancer Journal, Vol 12, Iss 4, Pp 1-9 (2022)
Abstract Phase 3 trials Viale-A and Viale-C evaluated health-related quality of life (HRQoL) in patients with AML unfit for intensive chemotherapy who received venetoclax (VEN) + (AZA) (Viale-A) or low-dose cytarabine (LDAC) (Viale-C) or placebo (PBO
Externí odkaz:
https://doaj.org/article/1528dc8b9be94e9dbe4fb679eb6e3aa0
Autor:
Anne Tierens, Tracy L. Stockley, Clinton Campbell, Jill Fulcher, Brian Leber, Elizabeth McCready, Peter J. B. Sabatini, Bekim Sadikovic, Andre C. Schuh
Publikováno v:
Current Oncology, Vol 28, Iss 2, Pp 1376-1387 (2021)
Measurable (minimal) residual disease (MRD) is an established, key prognostic factor in adult B-cell acute lymphoblastic leukemia (B-ALL), and testing for MRD is known to be an important tool to help guide treatment decisions. The clinical value of M
Externí odkaz:
https://doaj.org/article/8f0d09c1a92f4093bb4e91866492160c
Autor:
Ruiqi Chen, Xing Liu, Arjun D. Law, Solaf Kanfar, Dawn Maze, Steven M. Chan, Vikas Gupta, Karen W. Yee, Mark D. Minden, Aaron D. Schimmer, Andre C. Schuh, Caroline J. McNamara, Tracy Murphy, Anna Xu, Umberto Falcone, Jack Seki, Hassan Sibai
Publikováno v:
Current Oncology, Vol 28, Iss 1, Pp 128-137 (2020)
Background: venous thromboembolism (VTE) is a well-known complication in adults with acute lymphoblastic leukemia (ALL), especially in patients treated with asparaginase (ASNase)-including regiments. However, VTE risk in adult Philadelphia-positive A
Externí odkaz:
https://doaj.org/article/52f8617b934048549a4137619b3d7db4